What Does New advancements in BRD4 inhibition therapy ABBV-744 Mean?
In Segment C, individuals will receive ABBV-744 and oral navitoclax. In Section D, contributors will obtain ABBV-744 and ruxolitinib. Contributors will obtain treatment until eventually ailment progression or the individuals are unable to tolerate the study drugs.There might be better treatment burden for members On this trial in comparison to thei